Omalizumab biosimilar(jemincare)

奥马佐单抗生物类似药(济民可信)

Report date: 2022/06/08 13:47:39

Base Information

Drug NameOmalizumab biosimilar(jemincare)
Drug Alias NameAB1904Am15
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionImmunoglobulin E inhibitors
TargetsImmunoglobulin E
Therapy Area/IndicationsAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesJiangxi Jemincare Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangxi Jemincare Group Co Ltd
Inactive CompaniesN/A
Active IndicationsAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A